BACKGROUND Concurrent platinum-based radiochemotherapy has been recommended as a standard of care in patients with locally advanced squamous cell head and neck carcinomas. Unfortunately, there is a lack of level one evidence on best treatment approach for advanced hypopharyngeal cancer. This report aims to summarize the results of our study on concurrent radiochemotherapy in patients with advan...

We have synthesized graphene oxide (GO) nanosheets using modified Hummer's method and conjugated it with doxorubicin (DOx), an anticancer drug. Drug release kinetics from GO-DOx conjugate indicated the drug release at acidic pH. MTT assay performed on FaDu hypopharyngeal cancer cell lines revealed that the GO-DOx nanoconjugate inhibited cell proliferation more efficiently compared with pure DOx...

Squamous cell carcinoma of the larynx is currently the second most common malignancy of the airway after lung cancer,1 and hypopharyngeal cancer accounts for fewer than 5% of head and neck cancers.2 Different treatment options exist, and they can be surgical or nonsurgical, such as radiotherapy (RT) or chemoradiotherapy (CRT). In advanced stages of the disease, the treatment strategy has evolve...

Head and neck cancers includes oral, nasal and paranasal, nasopharyngeal, mesopharyngeal, hypopharyngeal, laryngeal, and salivary gland cancers, as well as cancers that involve the thyroid gland, ear, trachea, face, and neck. Epidemiological analysis of head and neck cancer cases in a single institution during a short period is extremely difficult because of its low incidence. We here assessed ...

Background Till not many years ago, the recommended treatment for advanced laryngeal cancer was a total laryngectomy followed by adjuvant radiation therapy. Studies conducted from 1980’s have broadened the therapeutic options, in the attempt to cure the cancer while sparing laryngeal functions. Functional surgery and a combination of chemotherapy (CT) and radiotherapy (RT) appears to be able to...

This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. With an age standardised incidence rate of 0.63 per 100 000 population, hypopharynx cancers account for a small proportion of the head and neck cancer workload in the UK, and thus suffer from the lack of high level evidence. This paper discusses the evidence bas...